| Name | Clotrimazole |
| Description | Clotrimazole (FB 5097), an imidazole derivative with a broad spectrum of antimycotic activity, inhibits biosynthesis of the sterol ergostol. |
| In vitro | Intradermal injection of Clotrimazole in mice stimulates capsaicin-sensitive and mustard oil-sensitive trigeminal neurons, inducing nocifensive behavior and thermal hyperalgesia. In TRPV1 knockout mice, Clotrimazole-induced pain behavior is inhibited by the TRPV1 antagonist BCTC [1,2,3,4-tetrahydro-6-trichloromethyl-pyrimidine-2-one]. |
| In vivo | In the CRI-G1 whole-cell of a rat insulinoma cell line, Clotrimazole antagonizes ADP-ribose-activated and single-channel currents. Clotrimazole effectively and rapidly inhibits parasite growth across five different strains of the malignant malaria protozoan. In HEK-293 cells expressing recombinant human TRPM2, Clotrimazole inhibits ADP-ribose-activated currents. At 2 mM concentration, Clotrimazole completely suppresses parasite replication, resulting in the destruction of host cells. Furthermore, Clotrimazole at concentrations ranging from 3 mM to 30 mM entirely inhibits TRPM2-mediated currents. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 6.88 mg/mL (19.94 mM), Sonication is recommended.
Ethanol : 64 mg/mL (185.6 mM)
|
| Keywords | Autophagy | Inhibitor | FB-5097 | Antibiotic | inhibit | FB5097 | Clotrimazole | Fungal | Bacterial |
| Inhibitors Related | Neomycin sulfate | Sulfamethoxazole sodium | Hydroxychloroquine | Guanidine hydrochloride | Doxycycline | Paeonol | Dimethyl sulfoxide |
| Related Compound Libraries | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Anti-Fungal Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Cosmetic Ingredient Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
